Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Pharmacology and Therapeutics
- Transplantation Medicine
- Signs and Symptoms-Clinical Findings
- Medical Radiography
- Dentistry and Oral Biology
- Renal Disease
- Gastroenterology
- Cardiovascular Medicine
Abstract
Citation: Ann Clin Case Rep. 2022;7(1):2257.DOI: 10.25107/2474-1655.2257
First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation
Emeline Christophel-Plathier1*, Vitor Mendes2, Francois Verdy2, Sylvain Mauron1 and Caroline Mury1
1Department Anesthesiology, Lausanne University Hospital (CHUV), Switzerland
2Department Cardiac Surgery, Lausanne University Hospital (CHUV), Switzerland
*Correspondance to: Emeline Christophel-Plathier
PDF Full Text Case Report | Open Access
Abstract:
Cardiac surgery with Cardiopulmonary Bypass (CPB) is a trigger of significant Systemic Inflammatory Response Syndrome (SIRS) with an accompanying cytokine release. Additional factors increasing the risk of post-operative SIRS include surgery itself, long CPB duration, and mechanical hemolysis and ischemia-reperfusion injuries. Cytosorb® is a hemoadsorption device that removes many cytokines from the blood. Pediatric patients with exaggerated pre-operative SIRS might be good candidates for an assessment of Cytosorb’s® usefulness. We present the case of a fullterm newborn with a hypoplastic left heart syndrome. Five days after birth, the patient underwent a Norwood stage I palliation under CPB with adjunction of Cytosorb®. Post-operative course was uneventful, hemodynamic adaptation was good, with rapid weaning off all amine infusions.
Keywords:
Cite the Article:
Christophel-Plathier E, Mendes V, Verdy F, Mauron S, Mury C. First Hemoadsorption during Cardiopulmonary Bypass in Neonate with Complex Cardiac Malformation. Ann Clin Case Rep. 2022; 7: 2257.